256 related articles for article (PubMed ID: 28339668)
1. Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth.
Warshaw MG; Siberry GK; Williams P; Decker MD; Jean-Philippe P; Lujan-Zilbermann J
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e69-e74. PubMed ID: 28339668
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
Siberry GK; Warshaw MG; Williams PL; Spector SA; Decker MD; Jean-Philippe P; Yogev R; Heckman BE; Manzella A; Roa J; Nachman S; Lujan-Zilbermann J;
Pediatr Infect Dis J; 2012 Jan; 31(1):47-52. PubMed ID: 21987006
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
Siberry GK; Williams PL; Lujan-Zilbermann J; Warshaw MG; Spector SA; Decker MD; Heckman BE; Demske EF; Read JS; Jean-Philippe P; Kabat W; Nachman S;
Pediatr Infect Dis J; 2010 May; 29(5):391-6. PubMed ID: 20431379
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
[TBL] [Abstract][Full Text] [Related]
7. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
8. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.
Memish ZA; Yezli S; Almasri M; Assiri A; Turkestani A; Findlow H; Bai X; Borrow R
Int J Infect Dis; 2014 Nov; 28():171-5. PubMed ID: 25307887
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
[TBL] [Abstract][Full Text] [Related]
13. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus.
Lujan-Zilbermann J; Warshaw MG; Williams PL; Spector SA; Decker MD; Abzug MJ; Heckman B; Manzella A; Kabat B; Jean-Philippe P; Nachman S; Siberry GK;
J Pediatr; 2012 Oct; 161(4):676-81.e2. PubMed ID: 22622049
[TBL] [Abstract][Full Text] [Related]
15. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
18. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
[TBL] [Abstract][Full Text] [Related]
19. Meningococcal group A, C, Y and W-135 conjugate vaccine.
Harrison LH; Mohan N; Kirkpatrick P
Nat Rev Drug Discov; 2010 Jun; 9(6):429-30. PubMed ID: 20514064
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.
Piazza FM; Virta M; Paassilta M; Ukkonen B; Ahonen A; Esteves-Jaramillo A; Forsten A; Seppa I; Ding J; Neveu D; Jordanov E; Dhingra MS
Hum Vaccin Immunother; 2022 Dec; 18(1):1-10. PubMed ID: 34085900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
